Separately, Zacks Investment Research downgraded shares of Basilea Pharmaceutica from a hold rating to a sell rating in a research report on Friday, January 3rd.
BPMUF stock traded up $5.56 during trading on Wednesday, reaching $60.05. The stock had a trading volume of 35 shares, compared to its average volume of 4. Basilea Pharmaceutica has a one year low of $36.59 and a one year high of $60.05. The company’s 50 day moving average is $48.38 and its two-hundred day moving average is $42.91.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers isavuconazole, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, the European Union, and internationally under the Cresemba brand.
Featured Story: How prevalent are 12b-1 fees?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.